Media Release

ZURICH, SWITZERLAND - JANUARY 19, 2015

Danaher controls more than 98% of Nobel Biocare and started squeeze out procedure; Nobel Biocare applied for delisting

Nobel Biocare Holding AG has been informed that Danaher Corporation today filed a petition with the Commercial Court of the Canton of Zurich for the annulation (Kraftloserklärung) of the remaining publicly held registered shares of Nobel Biocare against payment of the offer price that had been offered and paid by Danaher in its public tender offer for all publicly held registered shares of Nobel Biocare.

Also, Nobel Biocare today filed petitions with SIX Swiss Exchange for the de-listing (Dekotierung) of the registered shares of Nobel Biocare from SIX Swiss Exchange and for exemptions from certain obligations under the Listing Rules of SIX Swiss Exchange, including in particular from certain publicity obligations.

Danaher's intentions with respect to these petitions had been disclosed and announced in its public tender offer documents.

Contact information:

Süha Demokan

Investor & Corporate Relations

Tel: +41 43 211 42 30, +41 79 430 81 46

suha.demokan@nobelbiocare.com

Disclaimer

This media release contains forward-looking statements based on beliefs of Nobel Biocare's management. When used in this media release, words such as "anticipate", "believe", "estimate", "expect", "intend", "plan" and "project" are intended to identify forward-looking statements. They may involve risks and uncertainties, including technological advances in the medical field, product demand and market acceptance, the effect of economic conditions, the impact of competitive products and pricing, foreign currency exchange rates and other risks. These forward-looking statements reflect the views of Nobel Biocare as of the date made with respect to future events and are subject to risks and uncertainties. All of these forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results or experience could differ materially from the forward-looking statements. Nobel Biocare disclaims any intention or obligation to update these forward-looking statements.


Media Release (PDF)



Provider
 Channel
 Contact
Tensid Ltd., Switzerland
www.tensid.ch


 newsbox.ch
www.newsbox.ch


 Provider/Channel related enquiries
marco@tensid.ch
+41 41 763 00 50